Chr. Hansen’s human milk oligosaccharide (HMO) 6’-Sialyllactose sodium salt (6’-SL) has been approved for the highest use levels in infant formula and follow-on formula in the EU.
Marketed under MyOli 6’-SL HMO, 6’-SL is authorised for the EU market and under proprietary protection for five years.
According to Chr. Hansen, 6′-SL HMO can reduce the risk of adhesion of harmful bacteria and their proteins and support brain development in infants, by supplying sialic acid – an essential building block for neurons.
The Danish enzyme producer now has EU authorisation for all five HMOs in its MyOli 5 HMO Mix, including 2’-FL, 3-FL, LNT, 3’-SL and 6’-SL, which are approved at the highest use levels in the industry.
Jesper Sig Mathiasen, senior vice president, Chr. Hansen HMO, said: “The fact that Chr. Hansen MyOli 5 HMO Mix is now approved for use in the EU at the highest use levels is an important milestone. It means that Chr. Hansen can now supply a blend of five HMOs bringing infant nutrition solutions closer to breast milk, to the benefit of infants who cannot be breastfed for various reasons. The European approval is also an important step towards using HMOs at natural concentration levels in infant formula and follow-on formula.”
HMOs are said to be the third most abundant solid component of breast milk and are known in many different variations.
© FoodBev Media Ltd 2024
